-
Removing Pollen Interference in EEM Bioaerosol Screening
2026-09-25
Zhang and colleagues investigated how pollen affects excitation–emission matrix fluorescence classification of hazardous biological samples and tested spectral preprocessing, feature transformations, and random forest modeling as ways to reduce that interference. Fast Fourier transform processing gave the strongest reported improvement, with classification accuracy reaching 89.24%; the results support further development of rapid screening methods while leaving external validation and field performance to be established.
-
From DNA Synthesis to Wound-Healing Decisions
2026-09-25
A translational perspective on using EdU-based S-phase measurements to connect epithelial cell-cycle mechanisms with experimental decisions in diabetic wound research—while keeping the evidence, assay readouts, and clinical claims appropriately distinct.
-
Homoharringtonine Against SARS-CoV-2: Study Findings
2026-09-24
A 2025 study reports that homoharringtonine inhibited four tested coronaviruses in vitro and describes viral-load reductions in mouse and small human cohorts after nasal or nebulized administration. The findings support further evaluation of this protein-synthesis inhibitor as a possible early antiviral strategy, but the limited clinical evidence does not establish efficacy or dosing for general use.
-
Anlotinib hydrochloride: Angiogenesis Assay Guide
2026-09-24
Use Anlotinib hydrochloride to connect VEGFR2, PDGFRβ, and FGFR1 blockade with measurable endothelial phenotypes—not just a single kinase readout. This workflow guide pairs migration and tube-formation assays with signaling and viability controls to help distinguish anti-angiogenic activity from nonspecific cell loss.
-
Protease Inhibitor Cocktail for Sensitive Assays
2026-09-23
Preserve labile proteins during extraction without adding EDTA when phosphorylation analysis or divalent-cation-dependent assays matter. This practical guide shows how to dilute the 200X cocktail, apply it across Western blot and immunoprecipitation workflows, and troubleshoot what it does—and does not—inhibit.
-
QPRT, P2Y11 Signaling, and Breast Cancer Invasion
2026-09-23
Liu et al. show that elevated quinolinate phosphoribosyltransferase (QPRT) is associated with breast cancer invasiveness and promotes migration through a pathway involving purinergic signaling and myosin light chain phosphorylation. Pharmacological interference with P2Y11, Rho, ROCK, PLC, or MLCK reduced the QPRT-associated phenotype, providing a mechanistic framework for studying metabolism–cytoskeleton coupling in cancer cells.
-
EdU Flow Cytometry Assay Kits (Cy5) Workflow
2026-09-22
Build a sensitive S-phase workflow around EdU incorporation, CuAAC click chemistry, and Cy5 flow detection without DNA denaturation. The approach is especially useful for testing epithelial repair biology, drug responses, genotoxicity, and cancer research cell proliferation alongside cell-cycle or antibody readouts.
-
Protease Inhibitor Cocktail for α-Synuclein Workflows
2026-09-22
Protect α-synuclein, chromogranin A, and phosphoprotein measurements during cell or tissue disruption with an EDTA-free, broad-spectrum formulation. This workflow-focused guide shows how to preserve lysate quality for Western blotting, co-immunoprecipitation, kinase assays, and Parkinson’s disease models without intentionally chelating divalent cations.
-
Acetylcysteine in Redox-Aware Cancer Assays
2026-09-21
Acetylcysteine and N-acetyl-L-cysteine can do more than replenish glutathione: they can reshape how oxidative-stress and nanomedicine assays are interpreted. This guide connects NAC chemistry with practical controls, model selection, and insights from a metastatic breast-cancer nanoplatform study.
-
Dextran sulfate sodium salt: DSS colitis workflow
2026-09-21
Build a reproducible mouse intestinal inflammation model with DSS while separating epithelial injury from mucosal repair. This workflow connects dose control, time-resolved tissue collection, and GPR35–KLF5 pathway assays for ulcerative colitis research and therapeutic screening.
-
ENaC Processing in Rat Kidney: Salt Loading and ADH
2026-09-20
The reference study shows that acute sodium repletion rapidly suppresses processed ENaC in rat kidney despite sustained aldosterone, whereas dDAVP increases both processed and full-length channel subunits. These findings support a model in which sodium loading and ADH regulate ENaC through distinct, aldosterone-independent effects on trafficking and synthesis.
-
Protease Inhibitor Cocktail for ATII Assays
2026-09-19
Protect DRP1, phospho-DRP1, and glycolysis-associated proteins during ATII-cell lysis with an EDTA-free formulation designed for phosphorylation-sensitive workflows. This guide pairs the cocktail with hyperoxia models, Western blotting, co-immunoprecipitation, and metabolic phenotyping while addressing DMSO, phosphatase, and sample-handling variables.
-
mCherry mRNA: Reporter to Translational Readout
2026-09-18
A thought-leadership guide to using Cap 1-capped, modified-nucleotide mCherry mRNA as a mechanistically informed reporter for delivery, formulation, and translational research, with kidney-targeted nanoparticle studies providing a practical framework for validation.
-
NF 449 in Reliable Platelet Assays
2026-09-18
NF 449 (SKU B6716) helps researchers separate ATP-sensitive platelet signaling from nonspecific loss of cellular or platelet viability. This scenario-based guide covers receptor selectivity, assay controls, preparation, interpretation, and practical vendor-selection criteria for reproducible platelet activation and antithrombotic agent research.
-
SN-38 Disrupts FUBP1–FUSE DNA Binding
2026-09-17
The reference study identified camptothecin and SN-38 as inhibitors of the FUBP1–FUSE interaction, adding a transcriptional mechanism to their established topoisomerase I activity. Its biochemical screening and HCC cell experiments suggest that disrupting FUBP1-dependent gene regulation may contribute to the anticancer effects of SN-38, while also defining important limits for translation into other tumor models.